NDAORALTABLET
Approved
Jul 2017
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
5/8 — Partial
ZYPITAMAG (pitavastatin magnesium) by Medicure is hydroxymethylglutaryl-coa reductase inhibitors [moa]. Approved for hmg-coa reductase inhibitor [epc]. First approved in 2017.
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYPITAMAG is an oral tablet containing pitavastatin magnesium, an HMG-CoA reductase inhibitor (statin) used to lower cholesterol and reduce cardiovascular risk. It works by inhibiting the enzyme responsible for cholesterol synthesis in the liver. The magnesium salt formulation offers improved bioavailability compared to earlier pitavastatin formulations.
$0.004BPart D
Peak4.2 years to LOEProduct is at peak lifecycle with modest Part D utilization (~8K claims), indicating stable but niche positioning in a crowded statin market with limited team expansion.
Mechanism of Action
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacologic Class:
HMG-CoA Reductase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on ZYPITAMAG at Medicure? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.